CYCC Quote, Financials, Valuation and Earnings

Lixte Biotechnology Holdings has a net margin of -19570% compared to Cyclacel Pharmaceuticals's net margin of --. Cyclacel Pharmaceuticals's return on equity of -2462.6% beat Lixte Biotechnology Holdings's return on equity of --.

Cyclacel Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 1736.27%. On the other hand Lixte Biotechnology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Cyclacel Pharmaceuticals has higher upside potential than Lixte Biotechnology Holdings, analysts believe Cyclacel Pharmaceuticals is more attractive than Lixte Biotechnology Holdings.

Cyclacel Pharmaceuticals has a beta of -0.039, which suggesting that the stock is 103.933% less volatile than S&P 500. In comparison Lixte Biotechnology Holdings has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.105%.

Cyclacel Pharmaceuticals has a quarterly dividend of $36.00 per share corresponding to a yield of 275.44%. Lixte Biotechnology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclacel Pharmaceuticals pays -- of its earnings as a dividend. Lixte Biotechnology Holdings pays out -- of its earnings as a dividend.

Cyclacel Pharmaceuticals quarterly revenues are $10K, which are larger than Lixte Biotechnology Holdings quarterly revenues of --. Cyclacel Pharmaceuticals's net income of -$81K is higher than Lixte Biotechnology Holdings's net income of -$709.6K. Notably, Cyclacel Pharmaceuticals's price-to-earnings ratio is -- while Lixte Biotechnology Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclacel Pharmaceuticals is 40.50x versus -- for Lixte Biotechnology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -19570% compared to Cyclacel Pharmaceuticals's net margin of -49.65%. Cyclacel Pharmaceuticals's return on equity of -2462.6% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Cyclacel Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 1736.27%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 28.21%. Given that Cyclacel Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cyclacel Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Cyclacel Pharmaceuticals has a beta of -0.039, which suggesting that the stock is 103.933% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Cyclacel Pharmaceuticals has a quarterly dividend of $36.00 per share corresponding to a yield of 275.44%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclacel Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Cyclacel Pharmaceuticals quarterly revenues are $10K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cyclacel Pharmaceuticals's net income of -$81K is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cyclacel Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclacel Pharmaceuticals is 40.50x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -19570% compared to Cyclacel Pharmaceuticals's net margin of --. Cyclacel Pharmaceuticals's return on equity of -2462.6% beat Oragenics's return on equity of --.

Cyclacel Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 1736.27%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2122.44%. Given that Oragenics has higher upside potential than Cyclacel Pharmaceuticals, analysts believe Oragenics is more attractive than Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals has a beta of -0.039, which suggesting that the stock is 103.933% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Cyclacel Pharmaceuticals has a quarterly dividend of $36.00 per share corresponding to a yield of 275.44%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclacel Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Cyclacel Pharmaceuticals quarterly revenues are $10K, which are larger than Oragenics quarterly revenues of --. Cyclacel Pharmaceuticals's net income of -$81K is higher than Oragenics's net income of -$2.2M. Notably, Cyclacel Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclacel Pharmaceuticals is 40.50x versus 0.43x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -19570% compared to Cyclacel Pharmaceuticals's net margin of --. Cyclacel Pharmaceuticals's return on equity of -2462.6% beat Theriva Biologics's return on equity of --.

Cyclacel Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 1736.27%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1349.28%. Given that Cyclacel Pharmaceuticals has higher upside potential than Theriva Biologics, analysts believe Cyclacel Pharmaceuticals is more attractive than Theriva Biologics.

Cyclacel Pharmaceuticals has a beta of -0.039, which suggesting that the stock is 103.933% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Cyclacel Pharmaceuticals has a quarterly dividend of $36.00 per share corresponding to a yield of 275.44%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cyclacel Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Cyclacel Pharmaceuticals quarterly revenues are $10K, which are larger than Theriva Biologics quarterly revenues of --. Cyclacel Pharmaceuticals's net income of -$81K is higher than Theriva Biologics's net income of -$4.3M. Notably, Cyclacel Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cyclacel Pharmaceuticals is 40.50x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.